12,372 trials
Herpes Zoster
Primary: Number of Subjects With Vaccine Response to Anti-glycoprotein E (Anti-gE) Antibodies as Determined by the Enzyme-linked Immunosorbent Assay (ELISA). — 110; 104 Subjects
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Primary: Change in Mean Serum Copeptin From Baseline (a Reflection of Endogenous Vasopressin Production) at Week 2 — -0.86; 0.39 pmole/L — p=<0.01
Primary Insomnia · Secondary Insomnia
Primary: Change in Subjective Measures of Sleep Using Medical Outcomes Study -Sleep Scale, From Baseline at 1-week Follow-up — 15.8; 16.1 units on a scale — p=0.84
HBeAg-positive Chronic Hepatitis B
Primary: Percentage of Participants With Hepatitis B Virus (HBV) DNA < 29 IU/mL at Week 48 — 63.9; 66.8 percentage of participants
HBeAg-negative Chronic Hepatitis B
Primary: Percentage of Participants With Hepatitis B Virus (HBV) DNA < 29 IU/mL — 94.0; 92.9 Percentage of participants
Breast Cancer
Primary: Clinical Response (Complete or Partial Response) Rate (Cohort A) — 62.9; 74.8; 69.1 percentage of patients
Chemotherapy-induced Nausea and Vomiting
Primary: Proportion of Participants Receiving HEC With Complete Response in Overall Phase — 20; 15 Participants — p=0.397
Cocaine Dependence
Primary: Immediate Memory Task
Primary Immune Deficiency Disorders · Common Variable Immunodeficiency · X-linked Agammaglobulinaemia
Primary: Primary Bioequivalence Analysis - Area Under the Curve Within a 28-day Dosing Interval (AUC0-28) in Adult Subjects — 1.01; 1.01; 1.07; 1.07 ratio Gammaplex 10%/Gammaplex…
Primary Immunodeficiency Disease
Primary: Percentage of Participants Who Experienced at Least 1 Adverse Event Causally Related to the Administration of the Study Drug — 19.0 Percentage of participants
Chronic Kidney Disease Stage 3 and 4
Primary: Part 1: Paricalcitol Maximum Observed Plasma Concentration (Cmax) — 0.13 ng/mL
Localized Resectable Neuroblastoma · Localized Unresectable Neuroblastoma · Recurrent Neuroblastoma
Primary: Event-Free Survival (EFS) — 48.1; 62.9 Percentage of participants — p=0.1016
Idiopathic Pulmonary Fibrosis
Primary: Percentage of Participants With Adverse Events — 98.0 percentage of participants
Rheumatoid Arthritis
Primary: Core Study: Percentage of Participants Achieving an American College of Rheumatology Response 20 (ACR20) at Week 24 — 35.2; 35.2; 19.6 Percentage of Participants…
Pulmonary Arterial Hypertension
Primary: Change From Baseline to End of Study (EOS) in Height for Age. — -0.8; 0.32; -0.64; -0.74 Z-score